米氮平 (MTZ) 是一种具有特殊药理学特征的抗抑郁药物。它还具有出色的安全性和耐受性。本综述提供了 MTZ 的药理学最新进展，并总结了 MTZ 对不同疾病的作用的研究结果。由于去甲肾上腺素能和血清素能作用之间的协同作用，MTZ 被认为具有抗抑郁作用，可有效治疗重度抑郁症以及与癫痫、阿尔茨海默病、中风、心血管疾病和呼吸系统疾病相关的抑郁症。在癌症患者中，MTZ 显着减少悲伤、恶心、睡眠中断和疼痛，并提高生活质量。此外，它对帕金森病、精神分裂症、心境恶劣、社交焦虑症、酒精依赖、创伤后应激障碍、恐慌症、疼痛综合症、强迫症和睡眠障碍也有良好的效果。此外，MTZ 在与抑郁症相关的不同情况下具有潜在的治疗作用，例如肝脏、肾脏、心血管、呼吸系统、不孕症、重金属引起的神经毒性和瘙痒。有效的抗氧化、抗炎和抗凋亡生物活性介导了这些有希望的作用。这些科学研究的积极成果促使越来越多的临床试验在不同条件下进行黄金级特殊抗抑郁药的临床试验。© 2023。作者。

Mirtazapine (MTZ) is an antidepressant drug with an exceptional pharmacological profile. It also has an excellent safety and tolerability profile. The present review provides a pharmacological update on MTZ and summarizes the research findings of MTZ's effects on different diseases. MTZ is hypothesized to have antidepressant effects because of the synergy between noradrenergic and serotonergic actions and is effective in treating major depressive disorder and depression associated with epilepsy, Alzheimer's disease, stroke, cardiovascular disease, and respiratory disease. In cancer patients, MTZ significantly reduced sadness, nausea, sleep disruption, and pain and improved quality of life. Also, it has promising effects on Parkinson's disease, schizophrenia, dysthymia, social anxiety disorder, alcohol dependency, posttraumatic stress disorder, panic disorder, pain syndromes, obsessive-compulsive disorder, and sleep disorders. Additionally, MTZ is potentially therapeutic in different situations associated with depression, such as liver, kidney, cardiovascular, respiratory, infertility, heavy metal-induced neurotoxicity, and pruritus. Potent antioxidative, anti-inflammatory, and anti-apoptotic bioactivities mediate these promising effects. These positive outcomes of the scientific investigations motivate more and more clinical trials for a golden exceptional antidepressant in different conditions.© 2023. The Author(s).